drugset / Trial / NCT00447122
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Phase 1
Terminated
25 enrolled
Brown University
Memorial Hospital of Rhode Island · collabRhode Island Hospital · collabThe Miriam Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1000 mg | — |
| Subject | Lapatinib | Small molecule | 1500 mg | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |